Key Points
- Maze SVP Amy Bachrodt sold 2,500 shares on April 1 at an average price of $29.44 for $73,600, leaving her with 12,965 shares (a 16.17% decline in her position); the trade was executed under a pre-arranged Rule 10b5-1 plan.
- The April sale is part of recent insider activity—Bachrodt sold an additional 15,000 shares earlier this year (totaling 17,500 shares sold since January)—yet analysts remain largely bullish, with a MarketBeat consensus "Buy" rating and an average price target of $66.44 (several firms have raised targets into the $58–$68 range).
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) SVP Amy Bachrodt sold 2,500 shares of the stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $29.44, for a total value of $73,600.00. Following the completion of the transaction, the senior vice president owned 12,965 shares of the company's stock, valued at $381,689.60. This trade represents a 16.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Amy Bachrodt also recently made the following trade(s):
- On Monday, February 2nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $46.04, for a total value of $230,200.00.
- On Thursday, January 22nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $45.52, for a total transaction of $227,600.00.
- On Friday, January 2nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $39.15, for a total transaction of $195,750.00.
Maze Therapeutics Price Performance
Maze Therapeutics stock opened at $28.71 on Friday. Maze Therapeutics, Inc. has a fifty-two week low of $6.71 and a fifty-two week high of $53.65. The firm's 50 day simple moving average is $44.44 and its 200-day simple moving average is $37.87. The company has a market cap of $1.43 billion, a P/E ratio of -8.89 and a beta of 5.16.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.08.
Analysts Set New Price Targets
Several analysts have recently commented on the company. Wedbush raised their target price on Maze Therapeutics from $43.00 to $58.00 and gave the stock an "outperform" rating in a research report on Monday, March 16th. BTIG Research reissued a "buy" rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, March 25th. Mizuho raised Maze Therapeutics to a "strong-buy" rating in a research note on Wednesday, March 11th. Truist Financial began coverage on Maze Therapeutics in a research report on Tuesday, March 17th. They set a "buy" rating and a $68.00 price objective for the company. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of Maze Therapeutics in a report on Thursday, January 22nd. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $66.44.
Read Our Latest Stock Report on Maze Therapeutics
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. Royal Bank of Canada increased its position in Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company's stock worth $27,000 after purchasing an additional 363 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Maze Therapeutics in the 4th quarter valued at approximately $39,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Maze Therapeutics in the 4th quarter valued at approximately $43,000. California State Teachers Retirement System increased its holdings in Maze Therapeutics by 138.0% in the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company's stock worth $55,000 after buying an additional 766 shares during the last quarter. Finally, Ameritas Investment Partners Inc. raised its position in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock valued at $42,000 after acquiring an additional 738 shares in the last quarter.
About Maze Therapeutics
(
Get Free Report)
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
